Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Mallinckrodt
Johnson and Johnson
AstraZeneca
Harvard Business School

Last Updated: August 14, 2022

Investigational Drug Information for pyrotinib


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for pyrotinib?

pyrotinib is an investigational drug.

There have been 112 clinical trials for pyrotinib. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2021.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, and Lung Neoplasms. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Fudan University, and Sun Yat-sen University.

There are six US patents protecting this investigational drug and ninety international patents.

Recent Clinical Trials for pyrotinib
TitleSponsorPhase
A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung CancerJiangsu HengRui Medicine Co., Ltd.Phase 1/Phase 2
A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and TaxaneJiangsu HengRui Medicine Co., Ltd.Phase 3
Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038First Affiliated Hospital Xi'an Jiaotong UniversityPhase 2

See all pyrotinib clinical trials

Clinical Trial Summary for pyrotinib

Top disease conditions for pyrotinib
Top clinical trial sponsors for pyrotinib

See all pyrotinib clinical trials

US Patents for pyrotinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
pyrotinib See Plans and Pricing Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, Jiangsu, CN) See Plans and Pricing
pyrotinib See Plans and Pricing Method for preparing tyrosine kinase inhibitor and derivative thereof Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, Jiangsu, CN) See Plans and Pricing
pyrotinib See Plans and Pricing Method for preventing or treating tumor diseases with a combination of tyrosine kinase inhibitor and CDK4/6 inhibitor JIANGSU HENGRUI MEDICINE CO., LTD. (Jiangsu, CN) SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (Shanghai, CN) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Mallinckrodt
Johnson and Johnson
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.